- PDF Free Download

Size: px

Start display at page:

Download ""

Ashley Shelton
5 years ago
Views:

1 11 TH INTERNATIONAL WORKSHOP ON CO-INFECTION HIV & HEPATITIS LONDON, UNITED KINGDOM JUNE 2015 MEETING PROSPECTUS

2 CONTENT Introduction... 3 Workshop description... 4 Background... 4 Meeting Objectives... 4 Learning Objectives... 4 Format... 4 Unique Meeting Features... 5 Target audience... 5 Demographics... 5 Geographical distribution last meeting... 6 Program Committee... 7 Organizing Committee... 8 Scientific Committee... 9 Participants Feedback Personal benefits Content Lectures Metrics Pre-workshop communications Post-workshop communications Most effective elements...15 Quotes Summary

INTRODUCTION The HIV/Hepatitis Co-infection workshop was initiated 11 years ago to address the rising need among clinicians and researchers for a workshop specifically focusing on these very

3 INTRODUCTION The HIV/Hepatitis Co-infection workshop was initiated 11 years ago to address the rising need among clinicians and researchers for a workshop specifically focusing on these very challenging patients. With the success of antiretroviral therapy, HIV infected patients were seeing improvement in longevity, only to be challenged with the dangers and complications of their additional viral infection. Depending on the country - this was either a majority, or a significant minority of the HIV patients under care. Although HIV/Hepatitis co-infection was a small part of some major HIV conferences, the field lacked a dedicated meeting on this topic. Over the years more and more educational components were added given the growing needs of clinicians to keep up with the rapid developments. The HIV/Hepatitis Co-infection workshop still remains the only focused co-infection meeting in the field. The 2015-edition will continue to focus on developments in basic science, emerging therapies and clinical management. It will emphasize translational research and best practices in the clinical management of Hepatitis and HIV co-infection. We hope this information is of interest. Please contact us if specific information is missing and we will gladly provide you with additional documentation. We would surely welcome your suggestions for improvement of this workshop in order to best serve the community treating co-infected patients. On behalf of the Organizing Committee, SANJAY BHAGANI, MD Royal Free Hospital, London, United Kingdom MARK NELSON, MD Chelsea and Westminster Hospital, London, United Kingdom Chairs

4 WORKSHOP DESCRIPTION BACKGROUND Initiated 11 years ago, this annual workshop is the leading medical gathering for those involved in the clinical care of co-infected individuals. The program provides an excellent platform to exchange the medical information and new treatment results, and to discuss them with the experts active in the different disciplines (including Virology, Hepatology, Immunology, Infectious Disease and Primary Care). MEETING OBJECTIVES To gather clinicians involved in the treatment HIV and Hepatitis Co-infection in an interactive workshop setting To improve the basic knowledge of antiviral therapy and give basic guidance to healthcare professionals involved in treatment of co-infected patients To provide a platform for presentation and discussion of the latest developments in the field To map current studies and results To translate new data to treatment guidelines To educate clinicians on how to best implement current and new drugs LEARNING OBJECTIVES After participating in this activity, the participants will demonstrate the ability to: Optimally manage their patients with HIV/HCV co-infection and HIV/HBV co-infection, including strategies for avoiding drug-drug interactions and improving patient adherence to therapy. FORMAT The format of the workshop includes plenary expert presentations, discussion sessions on areas currently lacking consensus, and abstract-driven presentations. Experts in the area are invited to give state-of-the-art lectures and controversial patient cases are be discussed by expert panels. Although originally this meeting is abstract-driven, starting 2013 it was decided to emphasize the educational character of this meeting, limiting oral abstract presentations. Poster sessions remain a very important part of this workshop. To ensure the quality of accepted abstracts, all submitted abstracts go through a blind, peer-reviewed process conducted by the members of the Organizing and Scientific Committees. The below table shows the abstract submission statistics from the past four years: Total number accepted abstracts Oral presentations Poster presentations

5 UNIQUE MEETING FEATURES The International Co-infection workshop is a clinically focused workshop in which all world experts are present to share their experience and discuss their data. The cross-disciplinary sharing of information between hepatologists and infectious disease experts creates a unique opportunity to further improve the daily management of HIV and Hepatitis co-infected patients. TARGET AUDIENCE The primary target audience for the International Co-infection workshop are clinicians involved in daily care for coinfected patients. DEMOGRAPHICS Clinicians 78% 72% 72% 81% Researchers 11% 9% 11% 11% Post-graduate students 5% 4% 5% 3% Regulatory / Industry 4% 9% 4% 5% TOTAL number of participants GEOGRAPHICAL DISTRIBUTION LAST MEETING Belgium 12 Canada 24 Czech Republic 1 Egypt 4 Finland 5 France 27 Georgia 1 Germany 8 Greece 9 Italy 5 Israel 1 Latvia 1 Portugal 32 Romania 9 Spain 115 Sweden 2 Switzerland 2 The Netherlands 14 UK 27 USA 7 5

6 ORGANIZING COMMITTEE CHARLES BOUCHER, MD, PHD Erasmus Medical Center Rotterdam, the Netherlands DOUGLAS DIETERICH, MD Mount Sinai Medical Center New York, NY, USA KARINE LACOMBE, MD, PHD Hôpital Saint Antoine Paris, France MARK NELSON, MD Chelsea and Westminster Hospital London, UK MARION PETERS, MD University of California San Francisco, CA, USA MASSIMO PUOTI, MD Niguarda Cà Granda Hospital Milan, Italy June, London, United Kingdom 6

ORGANIZING COMMITTEE JÜRGEN ROCKSTROH, MD University

Hospital Joaquin Urbano Porto, Portugal VICENTE

JONATHAN SCHAPIRO, MD Sheba Medical Center Tel Aviv,

Cincinnati Cincinnati, OH, USA MARK SULKOWSKI, MD

7 ORGANIZING COMMITTEE JÜRGEN ROCKSTROH, MD University of Bonn Bonn, Germany RUI SARMENTO E CASTRO, MD Hospital Joaquin Urbano Porto, Portugal VICENTE SORIANO, MD, PHD Hospital Carlos III Madrid, Spain JONATHAN SCHAPIRO, MD Sheba Medical Center Tel Aviv, Israel KENNETH SHERMAN, MD, PHD University of Cincinnati Cincinnati, OH, USA MARK SULKOWSKI, MD Johns Hopkins University Baltimore, MD, USA June, London, United Kingdom 7

8 SCIENTIFIC COMMITTEE Sanjay Bhagani...Royal Free Hospital London, United Kingdom Raffaele Bruno...University of Pavia, Italy Giampiero Carosi...University of Brescia, Italy Andy Hoepelman...UMC Utrecht, the Netherlands Andrzej Horban...Hospital for Infectious Diseases, Poland Patrick Ingiliz...Medical Center for Infectious Diseases, Germany Arthur Kim...Massachusetts General Hospital, USA Marina Klein...McGill University Health Centre, Canada Sharon Lewin...Monash University Alfred Hospital, Australia Stefan Mauss...Center for HIV and Hepatogastroenterology, Germany Marina Nuñez...Wake Forest University Health Sciences, USA Juan A. Pineda...Hospital de Valme, Spain Stanislas Pol...Hôpital Cochin, France Giuliano Rizzardini...University of Milan, Italy Dominique Salmon...Hopital Cochin, France Ulrich Spengler...University of Bonn, Germany Cristina Tural...Hospital Germans Trias i Pujol, Spain June, London, United Kingdom 8

9 PARTICIPANTS FEEDBACK 2014 PERSONAL BENEFITS This meeting improved my: Agree Neutral Disagree Medical or practical knowledge 100% 0% 0% Care attitudes 67% 33% 0% Procedural or cognitive skills 89% 11% 0% Practice behaviour 78% 22% 0% Patient s clinical outcomes 88% 11% 0% I will change my daily practice after attending this workshop 88% I would recommend this workshop to my colleagues 100% I plan to attend this workshop again next year 78% CONTENT Agree Neutral Disagree The content of the meeting met my expectations 100% 0% 0% Sufficient time allocated for discussion during the meeting 90% 10% 0% The allocated time per presentation was sufficient 89% 11% 0% I perceived no commercial bias at the workshop 99% 9

PARTICIPANTS FEEDBACK 2014 FRIDAY 13 JUNE Pre-workshop Educational Course Practical Management of interactions

Back, PhD, University of Liverpool, UK Systematic review on non-invasive evaluation of liver fibrosis L.

M Pawlotsky, MD, PhD, University of Paris-Est, France Current treatment of HIV and HCV K.

Presentation 87% 13% 0% Content 97% 3% 0% Presentation 88% 9% 3% Content 91% 6% 3% Presentation 86% 14% 0% HBV

Peters, MD, UCSF, USA Content 91% 9% 0% Presentation 91% 9% 0% Options for HBV treatment in case of TDF toxicity

Cacoub, MD, Pierre and Marie Curie University, France Management of cirrhosis in HIVinfected patients V.

10 PARTICIPANTS FEEDBACK 2014 FRIDAY 13 JUNE Pre-workshop Educational Course Practical Management of interactions between DAA and ARVs D. Back, PhD, University of Liverpool, UK Systematic review on non-invasive evaluation of liver fibrosis L. Castera, MD, PhD, University of Paris - Nord, France Virological monitoring of HCV treatment in the era of DAA J.M Pawlotsky, MD, PhD, University of Paris-Est, France Current treatment of HIV and HCV K. Sherman, MD, PhD, University of Cincinnati, USA Content 93% 7% 0% Presentation 97% 3% 0% Content 94% 6% 0% Presentation 87% 13% 0% Content 97% 3% 0% Presentation 88% 9% 3% Content 91% 6% 3% Presentation 86% 14% 0% HBV management in immunosuppressed patients M. Peters, MD, UCSF, USA Content 91% 9% 0% Presentation 91% 9% 0% Options for HBV treatment in case of TDF toxicity C. Isnard - Bagnis, MD, PhD, CHU Pitié-Salpétrière, France Non-hepatic consequences of HCV and HBV infection P. Cacoub, MD, Pierre and Marie Curie University, France Management of cirrhosis in HIVinfected patients V. Mallet, MD, PhD, Université Paris- Descartes, France HCC in HIV patients: epidemiology and management O. Rosmorduc, MD, PhD, Hôpital Saint-Antoine, France Content 71% 20% 9% Presentation 63% 29% 8% Content 84% 16% 0% Presentation 76% 22% 2% Content 87% 13% 0% Presentation 79% 18% 3% Content 89% 8% 3% Presentation 71% 19% 10% 10

PARTICIPANTS FEEDBACK 2014 Main Meeting Program Session 1: Towards Hepatitis C

Rockstroh, MD, University of Bonn, Germany Treatment as prevention in HCV N.

80% 18% 2% Presentation 88% 11% 2% Session 2: Acute Hep C, re-infection and special

Boesecke, MD, Bonn University Hospital, Germany Acute HCV reinfection and late relapse T.

Content 96% 0% 4% Presentation 92% 4% 4% Content 94% 3% 3% Presentation 88% 9% 3% FRIDAY

11 PARTICIPANTS FEEDBACK 2014 Main Meeting Program Session 1: Towards Hepatitis C eradication Changing epidemiology of HCV mortality and morbidity in HIV patients J. Rockstroh, MD, University of Bonn, Germany Treatment as prevention in HCV N. Martin, PhD, University of Bristol, UK Content 88% 12% 0% Presentation 93% 7% 0% Content 80% 18% 2% Presentation 88% 11% 2% Session 2: Acute Hep C, re-infection and special population Treatment of acute hepatitis C: what are the next standards C. Boesecke, MD, Bonn University Hospital, Germany Acute HCV reinfection and late relapse T. Martin, MD, Chelsea and Westminster Hospital, UK Managing HCV and HBV in children and pregnant women M. Klein, MD, MSc, McGill University, Canada Content 94% 3% 3% Presentation 91% 6% 3% Content 96% 0% 4% Presentation 92% 4% 4% Content 94% 3% 3% Presentation 88% 9% 3% FRIDAY 13 JUNE Session 3: Cost-effectiveness in hepatitis care and management Access to care and who should be treated for HCV S. Bhagani, MD, Royal Free Hospital, UK Content 89% 11% 0% Presentation 92% 6% 2% 11

PARTICIPANTS FEEDBACK 2014 Cost-effectiveness of DAA-based treatment Y.

10% 2% Treatment as prevention for HBV? K.

hepatitis in resourcelimited settings: challenges and constraints M.

UK DEBATE: Everyone should be treated with HCV/HIV K.

Nelson, MD, Chelsea and Westminster Hospital, UK Content 85% 13% 2% Presentation 90% 10% 0%

Challenges in treating Co-infected Patients S.

12 PARTICIPANTS FEEDBACK 2014 Cost-effectiveness of DAA-based treatment Y. Yazdanpanah, MD, PhD, Hôpital Bichat Claude Bernard, France Content 85% 15% 0% Presentation 88% 10% 2% Treatment as prevention for HBV? K. Brinkman, MD, PhD, OLVG, the Netherlands Content 94% 3% 3% Presentation 95% 5% 0% Viral hepatitis in resourcelimited settings: challenges and constraints M. Lemoine, MD, PhD, MRC, PROLIFICA, Gambia, Imperial College London, St Mary s Hospital, London, UK DEBATE: Everyone should be treated with HCV/HIV K. Sherman, MD, PhD, University of Cincinnati, USA M. Nelson, MD, Chelsea and Westminster Hospital, UK Content 85% 13% 2% Presentation 90% 10% 0% Content 97% 3% 0% Presentation 95% 5% 0% Session 4: Integrase Inhibitors in Clinical Practice Challenges in treating Co-infected Patients S. Bhagani, BSc, FRCP, Royal Free Hospital, UK Clinical Consideration in the Use of Integrase Inhibitors J. Schapiro, MD, Sheba Medical Centre, Israel Clinical case presentation M. Nelson, MD, Chelsea and Westminster Hospital, UK Content 85% 15% 0% Presentation 94% 3% 3% Content 84% 13% 3% Presentation 81% 19% 0% Content 96% 4% 0% Presentation 88% 8% 4% 12

Session 5: Innovative treatment strategies in viral hepatitis Hepatitis C: Interferon- and / or Ribavirin-free regimens M.

Serfaty, MD, Hôpital Saint- Antoine, France ROUNDTABLE DISCUSSION: Acute chronic re-infection and late relapse Panel members: K.

Schapiro, MD, Sheba Medical Centre, Israel Content 90% 6% 4% Presentation 87% 10% 3% Content 92% 8% 0% Presentation 86% 12% 2% Content 97% 3% 0% Presentation

data on IFNsparing and IFN-free regimens in HCV/HIV patients P.

13 Session 5: Innovative treatment strategies in viral hepatitis Hepatitis C: Interferon- and / or Ribavirin-free regimens M. Puoti, MD, Niguarda Ca Granda Hospital, Italy EASL update: lecture on HCV monoinfection L. Serfaty, MD, Hôpital Saint- Antoine, France ROUNDTABLE DISCUSSION: Acute chronic re-infection and late relapse Panel members: K. Sherman, MD, PhD, University of Cincinnati, USA V. Soriano, MD, PhD, Hospital Carlos III, Spain D. Dieterich, MD, Mount Sinai Medical Centre, USA J. Schapiro, MD, Sheba Medical Centre, Israel Content 90% 6% 4% Presentation 87% 10% 3% Content 92% 8% 0% Presentation 86% 12% 2% Content 97% 3% 0% Presentation 95% 5% 0% Session 6: Abstract session Abstract - driven presentations Content 82% 13% 5% Session 7: Practical management of patients on DAA Overview on latest data on IFNsparing and IFN-free regimens in HCV/HIV patients P. Ingiliz, MD, Medical Center for Infectious Diseases, Germany Drug resistance testing in era of new DAAs C. Sarrazin, MD, JW Goethe University Hospital, Germany DAA-based treatment in cirrhotic and post-transplanted patients A. Coilly, MD, Hôpital Paul Brousse, France Content 97% 3% 0% Presentation 95% 5% 0% Content 97% 3% 0% Presentation 95% 5% 0% Content 90% 10% 0% Presentation 87% 13% 0% 13

14 METRICS 2014 PRE-WORKSHOP COMMUNICATIONS Publicity through electronic newsletter Flyers at other meetings Endorsement by societies Publicity on conference websites Invitations from industry Publicity through associations and other organizations Frequency/ Number 5 newsletters (outreach: ca 3000 contacts) The flyer was distributed by the Organizing Committee and at 4-5 other meetings (among others AASLD, CROI and EASL) ANRS Yes Yes SFLS (HIV), SPILF (Inf. Diseases), AFEF (Hepatitis), ANRS, SNFGE, German AIDS Society, Dagnä, BHIVA, Società Italiana Malattie Infettive e Tropicali, Italian Association for the Study of the liver ATTENTION TO THIS MEETING WAS DRAWN BY Virology Education announcement 7% Virology Education website 8% Flyer at other meetings 3% Industry invite 35% Word of mouth 26% Previous workshop: I attend every year 21% POST-WORKSHOP COMMUNICATIONS % Frequency/Number Workshop materials Workshop materials including the program and abstract book for online viewing are available from the previous meetings section of the Virology Education website. The abstracts are published in Reviews in Antiviral Therapy & Infectious Diseases: Reviews in Antiviral Therapy & Infectious Diseases 2013_2 of which 275 hard copy editions were distributed. The abstracts were made available on the workshop s website ( virology-education.com/abstractbook/2014_2. pdf). The slides are online available ( 14

15 MOST EFFECTIVE ELEMENTS QUOTES Good and effective interaction with experts, clinical oriented information. The invited talks on treatments and outcomes Panel discussions, talks by experts - fantastic opportunity Pre workshop - very educational, a good start Summary of EASL (update) Overall good meeting. Enjoyed the general reviews and updates on pathogenesis of liver and extrahepatic complications Always very useful contents, clinically oriented. See you next year! 15

16 SUMMARY Since its initiation 11 years ago, the HIV/Hepatitis Co-infection workshop remains the only focused co-infection meeting in the field. The program provides an excellent platform to exchange the medical information and new treatment results, and to discuss them with the experts active in the different disciplines (including Virology, Hepatology, Immunology, Infectious Disease and Primary Care). The cross-disciplinary sharing of information between hepatologists and infectious disease experts creates a unique opportunity to further improve the daily management of HIV and Hepatitis co-infected patients. The Organizing Committee is pleased with the results of the 10 th International workshop on HIV and Hepatitis Co-infection. The workshop clearly meets a need for international interchange on this important topic. The Organizing Committee therefore looks forward to organizing the 11 th edition of the workshop and to welcoming returning and new participants on June 2015 in London. 16

MEETING PROSPECTUS 3 RD EUROPEAN WORKSHOP ON WORKSHOP ON HEALTHY LIVING WITH HIV.

MEETING PROSPECTUS 3 RD EUROPEAN WORKSHOP ON WORKSHOP ON HEALTHY LIVING WITH HIV. 3 RD EUROPEAN WORKSHOP ON WORKSHOP ON HEALTHY LIVING WITH HIV BARCELONA, SPAIN, TBC SEPTEMBER 2018 TBC MEETING PROSPECTUS www.hivhealthyliving.com www.expertmedicalevents.com ADVANCING HEALTH GLOBALLY